Journal
INFLAMMATORY BOWEL DISEASES
Volume 13, Issue 7, Pages 918-932Publisher
OXFORD UNIV PRESS INC
DOI: 10.1002/ibd.20129
Keywords
intestine; inflammation; neuropeptides; inflammatory bowel disease
Categories
Funding
- NIDDK NIH HHS [R01 DK47343, R0-1 DK33506, F32DK076412, R01 DK 60729] Funding Source: Medline
Ask authors/readers for more resources
Inflammatory bowel disease (11313) is a chronic, relapsing condition involving complex interactions between genes and the environment. The mechanisms triggering the initial attack and relapses, however, are not well understood. In the past several years the enteric nervous system (ENS) has been implicated in the pathophysiology of IBD. Both the ENS and the central nervous system (CNS) can amplify or modulate aspects of intestinal inflammation through secretion of neuropeptides that serve as a link between the ENS and CNS. Neuropeptides are defined as any peptide released from the nervous system that serves as an intercellular signaling molecule. Neuropeptides thought to play a potentially key role in IBD include substance P, corticotropin-releasing hormone, neurotensin, vasoactive intestinal peptide, mu-opioid receptor agonists, and galanin. This review focuses on the role of these neuropeptides in the pathophysiology of IBD and discusses the cell types and mechanisms involved in this process. The available evidence that neuropeptide blockade may be considered a therapeutic approach in both Crohn's disease and ulcerative colitis will also be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available